

Press release
22 November 2016



Enamine and Pcovery extend drug discovery collaboration

Kiev, Ukraine, and Copenhagen, Denmark, November 22nd, 2016: Enamine Ltd., a chemical company, producer of building blocks and screening libraries, and Danish biotech company Pcovery, have announced that they have extended their collaboration for the discovery of new drugs for the treatment of invasive fungal infections and platform technology development.

Since 2014, Enamine's role has gradually evolved from a hit-finding library provider to a trusted partner in the field of broadly applicable chemistry services. A rigorous evaluation and selection process carried out at Pcovery identified Enamine as a reliable partner that provides state-of-the-art chemistry solutions at any level from synthesis of small compound libraries and singletons, through route scouting and process optimisation as well as scale-up of leads.

Under the terms of the collaboration, Pcovery's dedicated full time equivalent (FTE) team benefit from instant access to Enamine's inventory of building blocks, a collection that has been recognised for its impeccable structural quality and significant innovative components. All project reagent costs are covered by the FTE rate in place. While Enamine's experts actively participate in new composition of matter generation, the IP produced in the collaboration solely belongs to Pcovery.

Asked about the collaboration, William Dalby-Brown, Chief Operator Officer at Pcovery commented: "With a plethora of CROs in the market, finding the right partner remains a challenge. Headcount is not everything; chemists' skills, creativity, experience and access to the impressive stock of contemporary building blocks were the most important factors that ultimately led us to choose Enamine. Their remarkable work in synthesising their collection of building blocks now helps us to accelerate our drug discovery projects. We can pick from their stock building blocks, whereas sourcing in other ways would incur both time and cost. Our strategic partner Enamine is demonstrating a key role in Pcovery's successful path towards discovery and development of novel anti-infective drug candidates, with a particularly strong potential for the formation of a defensive IP position."

"We are delighted to continue our collaboration with Pcovery and advance to the company's next level," added Michael Bossert, Head of Strategic Alliances at Enamine, continuing: "First recognition of our expertise came with our offering of library synthesis using our end-capping building blocks and scaffolds received from a CRO that had been working with Pcovery previously. A relationship built on trust was rapidly established with Pcovery, who was further convinced via our high level chemistry service, seamless collaboration communication and positive work environment stimulating fruitful ideas. This collaboration is another validation of Enamine cost effective benefit for early drug discovery activities."

ENDS

Notes to Editors:
Contacts:

Pcovery:
William Dalby-Brown

COO

E: wdb(@)pcovery.com

T: +45 5159 4567

Enamine Ltd.

Michael Bossert

Head Strategic Alliances

E: m.bossert(@)enamine.net

T: +38 044 537 32 18

Media enquiries

Lorna Cuddon, Zyme Communications

E: Lorna.cuddon@zymecommunications.com

Phone: +44 7811996942

About Enamine www.enamine.net

Established in Kiev, Ukraine in 1991, Enamine combines a CRO profile with production and multi-level supply of building blocks and screening libraries. The major catalogue assets of the company are dynamically evolving diverse collections of 170,000 building blocks and 2,150,000 screening compounds, which represents the largest of these collections in the world. The company offers services in organic synthesis, medicinal chemistry, biological screening, ADME-PK testing, and integrated discovery.

About Pcovery www.pcovery.com

Pcovery is a Danish Drug Discovery company focused on the development of a novel class of broad-spectrum antifungal treatments. The scientific basis of Pcovery is in-depth knowledge on the structure and biochemistry of membrane proteins, combined with state-of-the-art antimicrobial drug development and medicinal chemistry. The company was founded in 2009, and is backed by Boehringer Ingelheim Venture Fund, Wellcome Trust, Novo A/S, and CAPNOVA.